These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10730322)

  • 21. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
    AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generic substitution of antihypertensive drugs: does it affect adherence?
    Van Wijk BL; Klungel OH; Heerdink ER; de Boer A
    Ann Pharmacother; 2006 Jan; 40(1):15-20. PubMed ID: 16303985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Generic carbamazepine-induced subacute adrenal insufficiency?].
    Vergely N; Mounier C; Guy C; Millot L; Estour B
    Ann Med Interne (Paris); 2002 Nov; 153(7):481-2. PubMed ID: 12598835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Branded versus generic clozapine: bioavailability comparison and interchangeability issues.
    Lam YW; Ereshefsky L; Toney GB; Gonzales C
    J Clin Psychiatry; 2001; 62 Suppl 5():18-22; discussion 23-4. PubMed ID: 11305844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbamazepine and L-type calcium channel inhibitors: a binding assay study.
    Ngan ET; Vincent SR
    Biol Psychiatry; 1996 Jun; 39(11):979-81. PubMed ID: 9162212
    [No Abstract]   [Full Text] [Related]  

  • 26. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
    Duh MS; Cahill KE; Paradis PE; Cremieux PY; Greenberg PE
    Expert Opin Pharmacother; 2009 Oct; 10(14):2317-28. PubMed ID: 19663636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing "abuse-deterrence equivalence" for generic abuse-deterrent opioid formulations: A proposed development framework.
    Setnik B; Cone EJ
    J Opioid Manag; 2016; 12(2):96-100. PubMed ID: 27194193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Generic drugs].
    Lemye R
    Rev Med Brux; 2000 Sep; 21(4):A273-5. PubMed ID: 11068479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo equivalence testing of nanoparticulate intravenous formulations.
    Pathak SM; Ruby PK; Aggarwal D
    Drug Res (Stuttg); 2014 Apr; 64(4):169-76. PubMed ID: 24203084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiological, pharmacological and pathological factors affecting the pharmacokinetics of calcium entry blockers.
    Padrini R; Piovan D; Bova S; Moretto R; Cargnelli G; Ferrari M
    G Ital Cardiol; 1987 Sep; 17(9):786-90. PubMed ID: 3692080
    [No Abstract]   [Full Text] [Related]  

  • 31. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. When do differences in dissolution profiles predict clinical problems?
    Ngo SN
    J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660
    [No Abstract]   [Full Text] [Related]  

  • 34. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs.
    Lapatto-Reiniluoto O; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2001 Sep; 70(3):255-60. PubMed ID: 11557913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A critical assessment of generic substitution for the obstetrician-gynecologist.
    Keith LG; Oleszczuk JJ; Ahranjani M
    Int J Fertil Womens Med; 2001; 46(6):286-95. PubMed ID: 11795687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers.
    Mignini F; Tomassoni D; Streccioni V; Traini E; Amenta F
    Clin Exp Hypertens; 2008 Feb; 30(2):95-108. PubMed ID: 18293165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
    Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
    Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Debate: Substitution of generic drugs in epilepsy: is there cause for concern?
    Gidal BE; Tomson T
    Epilepsia; 2008 Dec; 49 Suppl 9():56-62. PubMed ID: 19087118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.